Select Language
VEGF R2
VEGF R2 Overview
| English Name | Vascular endothelial growth factor receptor 2 | Approved Drugs | 17 |
| Drugs in Clinical Trials | 55 | Target Synonym | EC:2.7.10.1，EC 2.7.10，VEGFR2，KDR，Vascular endothelial growth factor receptor 2，Fetal liver kinase 1，Kinase insert domain receptor，Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase)，Protein-Tyrosine Kinase Receptor Flk-1，FLK1，Tyrosine Kinase Growth Factor Receptor，Fetal Liver Kinase-1，Soluble VEGFR2，CD309 Antigen，EC 2.7.10.1，VEGFR-2，CD309，VEGFR，FLK-1，Vascular Endothelial Growth Factor Receptor-2 |
| Highest Development Stage | Approved | ||
| English Name | Vascular endothelial growth factor receptor 2 |
| Target Synonym | EC:2.7.10.1，EC 2.7.10，VEGFR2，KDR，Vascular endothelial growth factor receptor 2，Fetal liver kinase 1，Kinase insert domain receptor，Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase)，Protein-Tyrosine Kinase Receptor Flk-1，FLK1，Tyrosine Kinase Growth Factor Receptor，Fetal Liver Kinase-1，Soluble VEGFR2，CD309 Antigen，EC 2.7.10.1，VEGFR-2，CD309，VEGFR，FLK-1，Vascular Endothelial Growth Factor Receptor-2 |
| Approved Drugs | 17 |
| Drugs in Clinical Trials | 55 |
| Highest Development Stage | Approved |
VEGF R2 Product List
- Product Category
Protein (8)Cell (1)
- Product Status
Launched (9)
- Species
Human (7)Rhesus macaque (1)Mouse (1)
- Tag
His Tag (4)Strep Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)Fc Tag (1)- (1)
- Conjugate
Unconjugated (5)Biotin-labeled (1)- (1)PE Labeled (1)APC Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT CHEK-ATF044 |  Human | HEK293 | Human VEGF R2 (Luc) HEK293 Reporter Cell |  |  Add to Cart | ||
HOT KDR-H5227 | Human | HEK293 | Human VEGF R2 / KDR Protein, His Tag (MALS verified) |  |  |  | Add to Cart |
HOT KDR-H82E5 | Human | HEK293 | Biotinylated Human VEGF R2 / KDR Protein, Avitag™,His Tag |  | | | Add to Cart |
HOT VE2-H5255 | Human | HEK293 | Human VEGF R2 / KDR Protein, Fc Tag (MALS verified) |  | | | Add to Cart |
KDR-H5280 | Human | HEK293 | Human VEGF R2 / KDR Protein, Twin-Strep Tag (MALS verified) |  | | | Add to Cart |
KDR-HP227 | Human | HEK293 | PE-Labeled Human VEGF R2 / KDR Protein, His Tag (Site-specific conjugation) |  | | Add to Cart | |
VE2-HA224 | Human | HEK293 | APC-Labeled Human VEGF R2 / KDR Protein, His Tag (Site-specific conjugation) |  | | Add to Cart | |
VE2-M5258 |  Mouse | HEK293 | Mouse VEGF R2 / KDR Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | | Add to Cart |
VE2-C52H3 |  Rhesus macaque | HEK293 | Rhesus macaque VEGF R2 / KDR Protein, His Tag |  | | | Add to Cart |
Total: 9
- 1
VEGF R2 Background
Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
VEGF R2 Synonyms
KDR,CD309,FLK1,VEGFR,VEGFR2
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Zanzalintinib | XL-092 | Phase 3 Clinical | Exelixis Inc | Solid tumours; Leiomyosarcoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Simmitinib hydrochloride | SOMCL-15-290 | Phase 3 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
| Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) | Phase 3 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details | |
| Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) | BC-001; BC001 | Phase 3 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
| KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
| Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 3 Clinical | Astrazeneca Plc | Solid tumours; Ovarian Neoplasms; Leiomyosarcoma; Leukemia; Liver Neoplasms; Optic Nerve Glioma; Skin Melanoma; Head and Neck Neoplasms; Biliary Tract Neoplasms; Medulloblastoma; Lymphoma, B-Cell, Marginal Zone; Ependymoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Carcinoma, Renal Cell; Carcinoma; Spinal Cord Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Leukemia, Hairy Cell; Rhabdoid Tumor; Squamous Cell Carcinoma of Head and Neck; Cystadenoma, Serous; Cystadenocarcinoma, Serous; Cystadenocarcinoma, Mucinous; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia-Lymphoma, Adult T-Cell; Hormone-Resistant Prostate Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Carcinoma, Verrucous; Nasopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hypopharyngeal Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large-Cell, Immunoblastic; Salivary Gland Neoplasms; Lymphomatoid Granulomatosi | Details |
| Sitravatinib | MGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Mouth Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms | Details |
| Gentuximab | Phase 3 Clinical | Genescience Pharmaceuticals Co Ltd | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details | |
| Axitinib intravitreal implant (Ocular Therapeutix) | OTX-TKI | Phase 3 Clinical | Ocular Therapeutix Inc | Wet Macular Degeneration; Macular Degeneration; Diabetic Retinopathy | Details |
| Pulocimab | AK-109; AK109 | Phase 3 Clinical | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma | Details | |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody(Jingyitaixiang Technology Development) | JY-025 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| VEGFR2 peptide vaccine (VAXIMM) | VXM-01 | Phase 2 Clinical | Merck Serono | Glioblastoma; Pancreatic Neoplasms; Colorectal Neoplasms | Details |
| Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
| Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
| Olinvacimab | SSS-23; TTAC-0001 | Phase 2 Clinical | Pharmabcine | Glioblastoma; Triple Negative Breast Neoplasms; Neoplasms; Neoplasm Metastasis | Details |
| BR-55 | BR-55; BR55 CEUS | Phase 2 Clinical | Sonus Pharmaceuticals Ltd | Ovarian Neoplasms; Neoplasms; Contrast agents; Inflammation; Diagnostic agents | Details |
| Axitinib Implant（Aerie） | AR-14034 SR; AR-14034 | Phase 2 Clinical | Aerie Pharmaceuticals Inc | Macular Degeneration | Details |
| Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
| VEGFR-1/2 peptide vaccine (Keio University) | Phase 2 Clinical | Keio University | Neurofibromatoses; Brain Neoplasms; Glioma | Details | |
| Gersizangitide | AXT-107 | Phase 2 Clinical | AsclepiX Therapeutics Inc | Diabetic macular oedema; Macular Degeneration | Details |
| KDR2-2 | Phase 2 Clinical | Guangzhou Huiborui Biomedical Technology Co Ltd | Glaucoma, Neovascular; Neovascularization, Pathologic; Corneal Neovascularization | Details | |
| KHK-4951 | Phase 2 Clinical | Kyowa Kirin | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details | |
| CEP-11981 | ESK-981; CEP-11981; SSR-106462; BOL-303213X | Phase 2 Clinical | Sanofi | Bone metastases; Neoplasms; Adenoma, Islet Cell; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenosquamous; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms | Details |
| Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
| MSB-0254 | MSB-0254 | Phase 1 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd | Solid tumours | Details |
| EDP317 | ACTB-1003; EOC-317; EDP-317 | Phase 1 Clinical | Bayer AG, Act Biotech Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
| Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours | Details |
| VEGFR2 peptide vaccine (Tokyo University) | Phase 1 Clinical | University Of Tokyo | Pancreatic Neoplasms | Details | |
| Brivanib Alaninate | ZL-2301; BMS-540215; BMS-582664 | Phase 1 Clinical | Bristol-Myers Squibb Company | Colorectal Neoplasms; Carcinoma, Endometrioid; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Pulmonary Disease, Chronic Obstructive; Liver Neoplasms; Asthma; Adenocarcinoma, Clear Cell; Sarcoma; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Rectal Neoplasms; Solid tumours | Details |
| Ramucirumab biosimilar (Henlius) | HLX-12 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AVI-3207 | AVI-3207 | Phase 1 Clinical | Avixgen | Macular Degeneration | Details |
| Pamufetinib | TAS-115 | Phase 1 Clinical | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | Neoplasms | Details |
| NP-01 (SSY Group) | Phase 1 Clinical | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Prostatic Neoplasms; Lung Neoplasms | Details | ||
| nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
| DPH-001 | DPH-001; DPH001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| A-168 | A168; A-168 | Phase 1 Clinical | Klus Pharma Inc | Details | |
| MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
| ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
| RP-904 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Solid tumours | Details | |
| RA1115-B1 | RA1115-B1 | Phase 1 Clinical | Suzhou Raymon Pharmaceuticals Co Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| PZ-1 | PZ-1 | Phase 1 Clinical | Chongqing University Of Arts And Sciences | Solid tumours | Details |
| SYHA-1817 | SYHA-1817 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell | Details |
| Ramucirumab biosimilar (CTTQ) | Phase 1 Clinical | Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | ||
| LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
| Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms | Details |
| FNX-006 | FNX-006 | Phase 1 Clinical | Sichuan University, Chengdu Fannuoxi Biomedical Technology Co Ltd | Triple Negative Breast Neoplasms; Melanoma | Details |
| Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Sarcoma, Alveolar Soft Part; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Medullary thyroid cancer (MTC); Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma | Details |
| Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
| Axitinib | PF-01367866; AG-13736; AG-013736 | Approved | Pfizer Inc | 英立达, Inlyta | United States | Carcinoma, Renal Cell | Pf Prism Cv | 2012-01-27 | Lung Neoplasms; Carcinoma, Ductal; Uveal melanoma; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Prostatic Neoplasms, Castration-Resistant; Leukemia, Myeloid, Acute; Lymphoma; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Paraganglioma; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoid Tumor; Pheochromocytoma; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Kidney Neoplasms; Adrenal Cortex Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Pancreatic Neoplasms; Mesothelioma; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors | Details |
| Vorolanib | CM-082; X-82; EYP-1901 | Approved | Tyrogenex Inc | 伏美纳, DURAVYU™ | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Melanoma; Carcinoma, Non-Small-Cell Lung; Diabetic Retinopathy; Macular Degeneration; Carcinoma, Hepatocellular; Choroidal Neovascularization; Adenocarcinoma; Eye Diseases; Leukemia, Myeloid, Acute; Retinal Degeneration; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms | Details |
| Tivozanib | KRN-951; KHK-4951; KHK4951; UNII-172030934T; ASP-4130; Kil-8951; AV-951 | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda, FOTIVDA | EU | Carcinoma, Renal Cell | Recordati Netherlands BV | 2017-08-24 | Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Peritoneal Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Wet Macular Degeneration; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Ovarian Neoplasms | Details |
| Apatinib Mesylate | YN-968D1 | Approved | Advenchen Laboratories Llc | 艾坦, Aitan | Mainland China | Stomach Neoplasms | Jiangsu shengdi Medicine Co Ltd | 2014-10-17 | Carcinoma, Adenoid Cystic; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Lung Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Ovarian Neoplasms; Neoplasms; Nasopharyngeal Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Esthesioneuroblastoma, Olfactory; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms; Solid tumours; Head and Neck Neoplasms | Details |
| Ripretinib | DCC-2618 | Approved | Deciphera Pharmaceuticals | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Mastocytosis, Systemic; Neoplasms; Gastrointestinal Stromal Tumors | Details |
| Ramucirumab | IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 | Approved | Dyax Pharma | Cyramza | United States | Gastrointestinal Stromal Tumors | Eli Lilly And Company | 2014-04-21 | Urethral Neoplasms; Melanoma; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Metastatic breast cancer; Urologic Neoplasms; Ureteral Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Solid tumours; Breast Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms | Details |
| Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Kidney Neoplasms; Skin Melanoma; Teratoma; Liver Neoplasms; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Lymphoma, B-Cell; HIV Infections; Fibrosarcoma; Intestinal Neoplasms; Fibromatosis, Aggressive; Leukemia; Lymphoma, B-Cell, Marginal Zone; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Abdominal Neoplasms; Pelvic Neoplasms; Polycythemia Vera; Thoracic Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoma; Histiocytoma, Malignant Fibrous; Hemangioblastoma; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Nose Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic neuroendocrine tumors (pNET); Plasmacytoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Carcinoma, Transitional Cell | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Osteosarcoma; Germinoma; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Uterine Cervical Diseases; Genital Neoplasms, Female; Gliosarcoma; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Lung Neoplasms; Nasopharyngeal Carcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Psoriasis; Gastrinoma; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Neoplasm Metastasis; Breast Neoplasms, Male; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Paraganglioma; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Sarcoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Choriocarcinoma; Uterine Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Glioma; Carcinoma, Embryonal; Skin Melanoma; Neoplasms; Herpes Genitalis; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Insulinoma; Pheochromo | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
| Fruquintinib | HMPL-013; TAK-113 | Approved | Hutchison Medipharma Ltd | FRUZAQLA, Aiyoute, 爱优特, Elunate | Mainland China | Colorectal Neoplasms | Hutchison Medipharma Ltd | 2018-09-04 | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Metastatic breast cancer; Endometrial Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Neoplasms; Solid tumours; Colonic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Renal Insufficiency; Biliary Tract Neoplasms | Details |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Rhabdomyosarcoma; Solid tumours; Ovarian Neoplasms; Fibromatosis, Aggressive; Kidney Neoplasms; Leukemia, Myeloid; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Histiocytoma, Malignant Fibrous; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Islet Cell; Insulinoma; Esophageal Neoplasms; Vipoma; Hemangiosarcoma; Abdominal Neoplasms; Wilms Tumor; Hypertension, Portal; Thyroid Carcinoma, Anaplastic; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Lymphomatoid Granulomatosis; Carcinoma, Transitional Cell; Colonic Neoplasms; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Endocrine Neoplasia Type 2a; Lymphoma, Large-Cell, Immunoblastic; Leukemia-Lymphoma, Adu | Details |
| Vandetanib | AZD-6474; CH-331; ZD-6474 | Approved | Astrazeneca Plc | Zactima, Caprelsa | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Genzyme Corp | 2011-04-06 | Metastatic breast cancer; Pleural Effusion; Urethral Neoplasms; Colorectal Neoplasms; Gliosarcoma; Diffuse Intrinsic Pontine Glioma; Astrocytoma; Lymphoproliferative Disorders; Ureteral Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Ampullary Carcinoma; Lung Neoplasms; Thyroid Neoplasms; Prostatic Neoplasms; Glioma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Lymphoma; Multiple Endocrine Neoplasia Type 2b; Gallbladder Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Neoplasm Metastasis; von Hippel-Lindau Disease; Precancerous Conditions; Carcinoma, Transitional Cell; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Kidney Neoplasms; Biliary Tract Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Abdominal Neoplasms; Carcinoma, Renal Cell; Pheochromocytoma; Carcinoma; Intestinal Neoplasms; Glioblast | Details |
| Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Leukemia, Mast-Cell | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland